FDA nixes new gout use for Regeneron drug; Spain's Grifols hits estimates with $163M profit;

 @FiercePharma: WSJ's list of 25 Best CFOs includes 3 drug company execs: Biogen, Allergan, Perrigo. List | Follow @FiercePharma

> The FDA dashed Regeneron's ($REGN) immediate hopes for a vast expansion of its anti-inflammatory drug Arcalyst. The drugmaker had been aiming to market Arcalyst to prevent gout flare-ups, but the agency asked for more clinical data. Report

> The Spanish drugmaker Grifols posted a $163 million profit for the first half of the year, meeting analyst expectations. Report

> 23andMe asked FDA to approve 7 genetic tests that would be used to assess disease risk or determine how patients would respond to particular drugs. Report

> Watson Pharmaceuticals ($WPI) asked the FDA to approve a generic version of Xopenox HFA, a Sunovion Pharmaceuticals treatment for bronchospasm that brought in $148 million last year. Report

> Sunovion Pharmaceuticals has launched its allergy spray Zetonna, the only dry nasal aerosol approved by FDA. Release

> Some U.S. pharmacies are selling off their entire inventories into the gray market for resale at huge markups, congressional investigators found. Report

Biotech News

 @FierceBiotech: CIRM favors teamwork with $150M in new stem cell grants. Story | Follow @FierceBiotech

 @JohnCFierce: Deja vu: Dimebon (remember it?) promising in mouse study for Alzheimer's. Scientists want to go back, try again. Release | Follow @JohnCFierce

 @RyanMFierce: Biotech VC deals abound this week: Ultragenyx nailed down $15M, and now Mersana says it's found $27M more with help from deep pockets at NEA. | Follow @RyanMFierce

> Rare disease biotech nails down $15.1M in VC. Report

> Vertex surges as rival hep C contender plays catch-up in clinic. Story

> Dendreon shares plunge as new CEO brings out the ax (again). More

Medical Device News

@FierceMedDev: Italy's DiaSorin Group signed a Dx expansion deal with Trivitron for the Indian market. Asian expansion continues. Release | Follow @FierceMedDev

 @MarkHFierce: 23andMe will seek FDA 510(k) clearance for its new personalized DNA test, the company disclosed. Release | Follow @MarkHFierce

 @DamianFierce: Looking to boost its flagging CRM business, Boston Sci snagged CE marks for two MRI-friendly pacemakers. More | Follow @DamianFierce

> Medtronic nabs 510(k) for combination surgical device. Item

> Teleflex hit with Class I recall of venous catheter. Story

Pharma Manufacturing News

 @EricPFierce: It is out with the old and with the new at HGS now that GSK is in charge. More | Follow @EricPFierce

> Plant's IT mess nearly kills AZ growth in new markets. News

> Drug pricing figures into McKesson settlement, earnings. Article

Biotech Research News

> Another shot at treating Alzheimer's with Dimebon? Article

> 17 universities win NIH cash for tissue chip/drug safety testing. News

> CIRM favors teamwork with $150M in new stem cell grants. More

And Finally... Eli Lilly is studying how dogs can sense low blood sugar in humans. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.